What Buscapina Compositum N Treats: Main Uses and Benefits

Buscapina Compositum N is commonly used to help with acute or disruptive symptom patterns, often applied in clinical settings that involve acute or unstable symptom patterns, particularly those involving symptoms related to physical discomfort and increased neurological or muscular activity in the abdominal area.

This combination medicine is considered relevant for easing spasmodic pain associated with Universal Condition Frames such as conditions involving episodic or fluctuating manifestations. It is applied in addressing spasmodic pain in the stomach and intestinal illness, colic-type pain, and functional disorders of the biliary and urinary tracts and of the female genital organs (like dysmenorrhea).

The dual-action formulation is relevant when supportive symptom management is appropriate. The combined approach supports patients during episodes of heightened discomfort and may assist with maintaining functional stability when symptoms become more noticeable. This action contributes to easing the overall symptom load. This medicine is used for managing symptom clusters such as:

“spasmodic pain in stomach and intestinal illness, colic-type pain, and functional disorders of the biliary and urinary tracts and of the female genital organs.”

Quick Fact: May provide supportive relief for Spasmodic Abdominal Pain

Regulatory References

1. European Medicines Agency (EMA) Document

This section outlines the official eligibility and non-eligibility criteria for Buscapina Compositum N (hyoscine butylbromide and paracetamol combination), strictly as stated in government regulatory documents.

---

Eligibility Scope

Classification	Population/Condition
Allowed for Use	Adults and children generally over 12 years old (or 10 years old, depending on the formulation/label).
Not Recommended	Children under 10 or 12 years of age, pregnant women, and breastfeeding women.
Contraindicated	Patients with known hypersensitivity to the ingredients or NSAIDs.
Contraindicated	Myasthenia gravis, narrow-angle glaucoma, or prostatic hypertrophy (risk of urinary retention).
Contraindicated	Conditions causing obstruction, such as mechanical stenosis of the gastrointestinal tract, paralytic ileus, or megacolon.
Contraindicated	Severe hepatocellular insufficiency (Child-Pugh C) or manifest glucose-6-phosphate dehydrogenase (G6PD) insufficiency (due to the paracetamol component).

---

Condition-Specific Eligibility Restrictions

Use requires special caution in patients with liver dysfunction (e.g., Gilbert's syndrome), impaired renal function, or those prone to tachyarrhythmia or intestinal/urinary outlet obstructions. The medicine is not recommended for continuous daily use without investigating the underlying cause of the symptoms.

Interactions with other medicines and products

The interaction profile of this medicine is based on the distinct properties of its active ingredients, Acetaminophen and Hyoscine Butylbromide, as documented in regulatory sources.

Documented Interaction Patterns

Interaction Type	Interacting Substances/Category	Official Restriction or Outcome
Additive Pharmacodynamic Effects	Other Anticholinergic Agents (e.g., antidepressants, antipsychotics)	May intensify the anticholinergic effects of Hyoscine Butylbromide.
Metabolic Toxicity Risk	Enzyme Inducers (e.g., Barbiturates)	Increases the hepatotoxic potential of Acetaminophen through accelerated CYP-mediated metabolism.
Absorption/Clearance Alteration	Probenecid	Reduces the clearance of Acetaminophen.
	Cholestyramine	Reduces the absorption of Acetaminophen. Administration may require separation in time.
Gastrointestinal Motility	Dopamine Antagonists (e.g., Metoclopramide)	Results in diminished effects of both substances on gastrointestinal motility.

Formal Interaction Constraints

Co-administration with other medicinal products containing Paracetamol is restricted to prevent exceeding the maximum daily dose and to avoid the risk of severe liver damage. The regulatory documentation explicitly links chronic and excessive consumption of alcohol to an increased risk of severe hepatotoxicity when using the Acetaminophen component. For patients taking oral anti-coagulants (e.g., Warfarin), long-term use of the Acetaminophen component is advisable only under medical supervision due to an increased risk of bleeding. The intramuscular injection of the Hyoscine Butylbromide component is contraindicated in patients on anticoagulant therapy due to the risk of intramuscular haematoma.

The pharmacological action is defined by a dual-site mechanism that involves modulating muscle tone and nociceptive signaling through two distinct biological domains.

---

Peripheral Cholinergic Blockade for Spasmolysis

The first domain, mediated by Hyoscine Butylbromide, involves the competitive antagonism of muscarinic acetylcholine receptors on the smooth muscles of the digestive and urinary tracts. By blocking the natural cholinergic signal, the component initiates a cascade that reduces intracellular calcium mobilization, resulting in functional spasmolysis—the reduction of sustained smooth muscle tension. This peripheral action is structurally constrained, resulting in negligible penetration of the central nervous system.

---

Central Pathway Modulation for Analgesia

The second domain, centered on Acetaminophen, involves the modulation of nociceptive signaling within the Central Nervous System (CNS). Its mechanism includes the inhibition of central COX enzymes (reducing the formation of pain-sensitizing prostaglandins) and the modulation of key neural receptors like TRPV1 and CB1 via its metabolites. This central engagement modulates descending nociceptive pathways, leading to an elevation of the central pain perception threshold.

How to Use Buscapina Compositum N

This section outlines the administration guidelines for Buscapina Compositum N (Hyoscine Butylbromide 10 mg + Paracetamol 500 mg), focusing on the principles of use and dosing patterns.

---

Administration Scope

Detail	Instruction
Route of Administration	The medication is approved for oral administration as a film-coated tablet.
Standard Adult Dosing	The typical single dose is one to two tablets for adults and children over 10 years of age.
Dosing Frequency	The dose may be repeated up to three times daily.
Maximum Daily Dose	The total daily dose is strictly limited to six tablets (equivalent to 3000 mg Paracetamol and 60 mg Hyoscine Butylbromide).
Method of Intake	Tablets must be swallowed whole with sufficient water; they should not be crushed, chewed, or broken.

---

Procedural Constraints and Duration

Use of this fixed-dose combination product should not exceed a duration of three days unless medical professional guidance is provided. This constraint is intended to manage the duration of non-prescription use. Caution is advised regarding use in patients with impaired kidney or liver function, where dose adjustments or extended dosing intervals may be necessary to accommodate altered drug clearance.

---

Connection to the Overall Protocol

The guidelines establish a precise oral administration protocol that defines the standardized application of the medicine. This protocol mandates both the dosage range and the frequency, while imposing a strict maximum daily dose to guide appropriate use. Adherence to swallowing the tablet whole is required to maintain the intended release profile of the dual active ingredients.

Evidence for Spasmodic Pain in the Gut and Urinary Tracts

Research included large-scale Randomized Controlled Trials (RCTs). These trials examined short-term changes in symptoms and were applied in studies examining patient-reported experiences in adult patients with recurrent crampy abdominal pain. The studies monitored outcomes related to physical discomfort, specifically measurements of pain intensity and frequency. Studies reported measurements of symptom outcomes when comparing the combination product to a non-active agent.

Research exploring outcomes when comparing the combination to its single components reported that the findings were mixed, with measured outcomes being similar in some trials. This evidence contributes to understanding symptom patterns over defined, intermediate timeframes.

---

Evidence for Functional Pain Disorders in Women

Research was applied in studies examining spasmodic conditions, including dysmenorrhea. Studies used smaller controlled designs alongside large-scale, Real-World Evidence (RWE) patient surveys. The research monitored outcomes reflecting daily functioning or activity level, such as interference with work and sleep, and examined the patterns of reported onset of symptom change. Study populations consisted of adult women with this condition.

RWE studies report how symptoms evolved in the observed populations, and findings help contextualize how patients reported their experience with episodic or acute changes. Comparative evidence is lacking against a broad range of other non-prescription treatments commonly used for this type of condition.

---

What is Still Uncertain About the Combination's Research

The body of evidence indicates that certainty remains low regarding consistent differences of the fixed-dose combination over its single components for all measured outcomes. Long-term effects are not fully established for the combination product. There is limited information for long-term outcomes, particularly regarding use extending beyond the standard 3-week trial duration. Subgroup findings are uncertain, with data for certain vulnerable groups, such as children under 12, remaining insufficient.

Key Studies & References ACTIVE PHARMACOVIGILANCE - Pharmacovigilance Plan Buscapina Compositum N - Submitted document 2015DEC28 (HMA/EMA Regulatory Filing)

Common questions about Buscapina Compositum N (FAQ)

---

Q: What is Buscapina Compositum N used for, besides the primary use?

A: In addition to general abdominal cramps, the official therapeutic indications for the medicine include providing relief from spasmodic pain across the gastrointestinal and genitourinary tracts. This includes pain classified as colic-type and discomfort related to functional disorders of the biliary tract and female genital organs, such as dysmenorrhoea (menstrual pain).

Q: How quickly does Buscapina Compositum N usually start working?

A: Product information generally describes the onset of action as relatively fast. Based on studies related to the active ingredients, official sources sometimes indicate that a patient may feel the onset of symptom relief within approximately 15 minutes of taking the oral tablet.

Q: What is the typical duration of effect for Buscapina Compositum N?

A: The official product information sets the maximum dosing frequency at up to three times per day. This dosing frequency supports the known half-life of the drug components, which suggests the effects of a single dose are expected to last for a defined period.

Q: Is it normal to feel drowsy after taking Buscapina Compositum N?

A: Official product information states that although effects on the central nervous system, such as drowsiness, are generally not anticipated because of how the drug works, official product information advises that patients who experience drowsiness or visual disturbances should not drive or operate machinery.

Q: How long does the medicine stay in the body after the last dose?

A: The official pharmacokinetic data describe how the body processes the medicine. For the hyoscine butylbromide component, the time it takes for half of the substance to be eliminated from the body—known as the terminal elimination half-life—is generally observed to be between 6 and 11 hours following oral intake.

Q: Does Buscapina Compositum N interact with common painkillers like ibuprofen or aspirin?

A: While the interactions section focuses on paracetamol-containing products, the official label does advise caution for individuals who have a known sensitivity to aspirin or other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Regulatory information indicates caution is advised when co-administering with other analgesics, particularly concerning the need for medical guidance.

Q: Can Buscapina Compositum N be taken alongside medications for thyroid conditions?

A: Official warnings indicate that special caution is advised for individuals with conditions that involve tachycardia, or a faster-than-normal heart rate. Since thyrotoxicosis (an overactive thyroid condition) is characterized by tachycardia, regulatory documents note that special caution is required in patients with such conditions.

Q: Is Buscapina Compositum N suitable for use by older adults or seniors?

A: Official warnings describe that special caution is required for use by older adults due to the increased risk of anticholinergic side effects. This is particularly relevant for seniors who may have underlying conditions like glaucoma or issues related to urinary retention, which are specifically listed as requiring careful consideration.

Q: Can Buscapina Compositum N cause constipation or diarrhea?

A: The combination medicine is known to have an anticholinergic effect, which can lead to inhibition of gastrointestinal movement. While some side effects like dry mouth are officially documented as uncommon, severe changes like constipation or diarrhea are typically not listed in the official tables as frequent side effects for this specific combination.

Q: Can Buscapina Compositum N cause changes in vision?

A: According to official regulatory warnings, the medicine is known to cause disturbances in visual accommodation (how the eye focuses). The label includes a warning that if a painful eye with loss of vision occurs, immediate medical attention is required due to the risk of triggering conditions like glaucoma.

Q: Are there specific instructions for what to do in case of accidental overdose?

A: Official overdose instructions detail that due to the potential for severe symptoms, such as liver damage from the paracetamol component, the need for immediate medical treatment is documented. Regulatory documents specify that certain measures, such as the use of an antidote like N-acetylcysteine, may be necessary as part of the treatment protocol.

Q: What types of pain is Buscapina Compositum N not intended to treat?

A: The regulatory indications specify that the medicine is designed to treat pain directly related to muscle spasms, such as cramping and colic. By definition of its pharmacological class, the medicine is not officially indicated for managing non-spasmodic forms of pain, such as chronic pain, nerve pain, or general muscular aches that do not involve smooth muscle cramping.

Q: Does Buscapina Compositum N have an anti-inflammatory effect?

A: Official regulatory descriptions of the drug's mechanism classify the paracetamol component solely as an analgesic (pain reliever) and the hyoscine component as an antispasmodic (muscle relaxer). The regulatory documents do not list an anti-inflammatory action as a primary or principal pharmacodynamic effect of the combination medicine.

Storage and Disposal Requirements for Buscapina Compositum N

The official regulatory labeling for Buscapina Compositum N specifies controlled conditions to maintain the product's stability and efficacy.

Storage Conditions

Item	Requirement
Temperature	Must not be stored above 25°C (25 degrees Celsius).
Protection	Keep in the original container/packaging to protect it from moisture and light.
Child Safety	Must be kept out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Unused or expired Buscapina Compositum N must be disposed of in accordance with local requirements and regulations. If no formal drug take-back program is available, national guidelines recommend mixing the product with an undesirable substance before sealing it in a container for disposal in household trash.